Migraine drug could halve the length of attacks, study shows

Researchers say erenumab is 'incredibly important step forward' for condition that affects 8.5 million people in UK

A new migraine drug that can halve the length of attacks has been hailed as "the start of real change" in how the condition is treated.

Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.